Surmodics | SRDX - Cash And Equivalent


Surmodics reported $36.11M in Cash and Equivalent for its fiscal quarter ending in September of 2024.





Cash And Equivalent Change Date
Abbott USD 8.52B 1.01B Dec/2025
Align Technology USD 1B 103.43M Sep/2025
Anika Therapeutics USD 57.48M 509K Dec/2025
Arrowhead Research USD 201.64M 112.94M Dec/2025
Artivion USD 64.91M 8.52M Dec/2025
Baxter International USD 1.97B 240M Dec/2025
Boston Scientific USD 1.96B 690M Dec/2025
Edwards Lifesciences USD 2.69B 587.2M Sep/2025
Haemonetics USD 363.37M 66.94M Dec/2025
Heron Therapeutics USD 43.07M 26.55M Sep/2025
J&J USD 19.71B 1.48B Dec/2025
Merit Medical Systems USD 446.4M 53.95M Dec/2025
Mesa Laboratories USD 28.98M 8.55M Dec/2025
Nektar Therapeutics USD 41.03M 1.96M Sep/2025
Option Care Health USD 232.62M 77.2M Dec/2025
Stryker USD 4.01B 755M Dec/2025
Surmodics USD 36.11M 11.81M Sep/2024
Trinity Biotech USD 1.34M 3.83M Sep/2025